Emily K. Kleczko
Affiliations: | 2000-2015 | Craniofacial Biology | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Google:
"Emily Kleczko"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Sisler DJ, Hinz TK, Le AT, et al. (2023) Evaluation of KRAS inhibitor responses in novel murine KRAS lung cancer cell line models. Frontiers in Oncology. 13: 1094123 |
Kleczko EK, Hinz TK, Nguyen TT, et al. (2023) Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity. Npj Precision Oncology. 7: 15 |
Kleczko EK, Poczobutt JM, Navarro AC, et al. (2023) Upregulation of complement proteins in lung cancer cells mediates tumor progression. Frontiers in Oncology. 12: 1045690 |
Kleczko EK, Le AT, Hinz TK, et al. (2023) Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response. Cancer Letters. 216062 |
Gadwa J, Bickett TE, Darragh LB, et al. (2021) Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer. Journal For Immunotherapy of Cancer. 9 |
Johnson AM, Kleczko EK, Nemenoff RA. (2020) Eicosanoids in Cancer: New Roles in Immunoregulation. Frontiers in Pharmacology. 11: 595498 |
Neuwelt AJ, Kimball AK, Johnson AM, et al. (2020) Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. Journal For Immunotherapy of Cancer. 8 |
Hinz TK, Kleczko EK, Singleton KR, et al. (2019) Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. Molecular Pharmacology |
Kleczko EK, Kwak JW, Schenk EL, et al. (2019) Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Frontiers in Immunology. 10: 954 |
Bullock BL, Kimball AK, Poczobutt JM, et al. (2019) Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC. Life Science Alliance. 2 |